Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy

被引:11
作者
Li Yu-feng [1 ,2 ]
Deng Zhi-kui [2 ]
Xuan Heng-bao [2 ]
Zhu Jia-bin [2 ]
Ding Bang-he [2 ]
Liu Xiao-ning [2 ]
Chen Bao-an [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Dept Haematol, Nanjing 210000, Jiangsu, Peoples R China
[2] First Hosp Huaian, Dept Haematol, Huaian 223300, Jiangsu, Peoples R China
关键词
homoharringtonine; chronic myelogenous leukaemia; long term efficacy; CHRONIC MYELOID-LEUKEMIA; INTERFERON-ALPHA; IMATINIB; RESPONSES; RECOMMENDATIONS; CYTARABINE; I/II;
D O I
10.3760/cma.j.issn.0366-6999.2009.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Homoharringtonine (HHT) is effective in treating late stage chronic myelogenous leukaemia (CIVIL), but little is known about long term maintenance during complete cytogenetic response. Long term efficacy and toxicity profiles of low dose HHT were evaluated in this study. Methods One hundred and six patients with CIVIL received 1.5 mg/m(2) of HHT alone by continuous daily infusion for seven to nine days every four weeks. Of 79 patients in the control group, 31 were treated with interferon alpha (IFN-alpha) and 48 with hydroxycarbamide. For 17 patients who failed to achieve cytogenetic response within 12 months' treatment of IFN-alpha, HHT was administered. Quantitative RT-PCR was used to detect the BCR-ABL mRNA expression in 36 Philadelphia positive CML patients enrolled after 2007. Haematological and cytogenetic responses were evaluated in all patients at the 12th month of follow-up. Long term efficacy was assessed in a follow-up with a median time of 54 months (12 months-98 months). Results After 12 months of therapy, cytogenetic response rate of the HHT IFN-a and hydroxycarbamide groups were 39/106, 14/31 and 3/48, and corresponding molecular cytogenetic response rates 6/18, 3/8 and 0. Of the 17 patients who received HHT as salvage treatment, 6 achieved cytogenetic response (3 major). At the 48 months' follow-up, cytogenetic response was maintained in 32/39 patients treated with HHT Patients who had cytogenetic response in HHT group or treated with IFN-a also showed longer median chronic durations, which were 45 months (12 months-98 months) and 49 months (12 months-92 months) respectively, indicating a longer survival time. Conclusions Low dose HHT alone showed considerable short term and long term efficacy in the treatment of late stage CIVIL. It may also be a good choice for patients who have failed imatinib, IFN-a treatment or haematopoietic stem cell transplantation or cannot afford these treatments. Chin Med J 2009;122(12):1413-1417
引用
收藏
页码:1413 / 1417
页数:5
相关论文
共 50 条
  • [41] Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature
    Kumar, Narender
    Ahluwalia, Jasmina
    Malhotra, Pankaj
    Sachdeva, Man Updesh Singh
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2013, 56 (03) : 303 - 305
  • [42] Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Faderl, Stefan
    Estrov, Zeev
    Giles, Francis
    Murgo, Anthony
    Ladle, Nakia
    Verstovsek, Srdan
    Cortes, Jorge
    CANCER, 2007, 109 (02) : 248 - 255
  • [43] Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
    Millot, Frederic
    Baruchel, Andre
    Guilhot, Joelle
    Petit, Arnaud
    Leblanc, Thierry
    Bertrand, Yves
    Mazingue, Francoise
    Lutz, Patrick
    Verite, Cecile
    Berthou, Christian
    Galambrun, Claire
    Bernard, Frederic
    Yacouben, Karima
    Bordigoni, Pierre
    Edan, Christine
    Reguerre, Yves
    Couillault, Gerard
    Mechinaud, Francoise
    Cayuela, Jean-Michel
    Guilhot, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (20) : 2827 - 2832
  • [44] Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Bashir, Qaiser
    De Lima, Marcos J.
    McMannis, John D.
    Garcia-Manero, Guillermo
    Shpall, Elizabeth
    Kantarjian, Hagop
    Cortes, Jorge E.
    O'Brien, Susan M.
    Jones, Dan
    Qazilbash, Muzaffar
    Wei, Wei
    Giralt, Sergio A.
    Champlin, Richard E.
    Hosing, Chitra
    LEUKEMIA & LYMPHOMA, 2010, 51 (08) : 1478 - 1484
  • [45] Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
    Cortes, Jorge
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Jones, Dan
    Faderl, Stefan
    Ebarb, Theresa
    Giles, Francis
    Thomas, Deborah
    Kantarjian, Hagop
    CANCER, 2007, 110 (09) : 2000 - 2006
  • [46] Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
    Mace, Morgan L.
    Dahl, Jenny
    Jabbour, Elias J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 999 - 1007
  • [47] Chronic myelogenous leukemia: diagnosis and treatment
    Demeter Judit
    Poros Anna
    Bodor Csaba
    Horvath Laura
    Masszi Tamas
    ORVOSI HETILAP, 2016, 157 (37) : 1459 - 1468
  • [48] Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
    Cervantes, Francisco
    Lopez-Garrido, Pilar
    Montero, Maria-Isabel
    Jonte, Fermin
    Martinez, Jesus
    Hernandez-Boluda, Juan-Carlos
    Calbacho, Maria
    Sureda, Anna
    Perez-Rus, Gloria
    Nieto, Jose B.
    Perez-Lopez, Cristina
    Roman-Gomez, Jose
    Gonzalez, Marcos
    Pereira, Arturo
    Colomer, Dolors
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1317 - 1324
  • [49] Evolution of Therapies for Chronic Myelogenous Leukemia
    Santos, Fabio P. S.
    Kantarjian, Hagop
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CANCER JOURNAL, 2011, 17 (06) : 465 - 476
  • [50] miRNAs as Biomarkers in Chronic Myelogenous Leukemia
    Kotagama, Kasuen
    Chang, Yung
    Mangone, Marco
    DRUG DEVELOPMENT RESEARCH, 2015, 76 (06) : 278 - 285